Ryan J. Watts

CIK: 0001724310

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (41.7%)

Position reduction

Option Exercises (M)3 (25.0%)

Derivative conversions

Awards (A)2 (16.7%)

Compensation grants

Other (G, F, J, C, D, …)2 (16.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

DNLI

Denali Therapeutics Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

DNLI
Denali Therapeutics Inc.
Aug 12, 2026
Gift(G)
Indirect
32.2K shares-
DNLI
Denali Therapeutics Inc.
Jan 6, 2026
Sale(S)
Direct
35.2K shares at avg. $16.50$581K
DNLI
Denali Therapeutics Inc.
Jan 3, 2026
Award(A)
Direct
79K shares-
DNLI
Denali Therapeutics Inc.
Sep 3, 2025
Gift(G)
Indirect
50K shares-
DNLI
Denali Therapeutics Inc.
Jul 9, 2025
Sale(S)
Direct
495.3K shares at avg. $15.00$7.4M
DNLI
Denali Therapeutics Inc.
Jul 9, 2025
Exercise(M)
Direct
455.3K shares at avg. $0.68$310K
DNLI
Denali Therapeutics Inc.
Jul 9, 2025
Exercise(M)
Direct
40K shares at avg. $5.28$211K
DNLI
Denali Therapeutics Inc.
Jan 7, 2025
Sale(S)
Direct
7.7K shares at avg. $20.81$159K
DNLI
Denali Therapeutics Inc.
Jan 6, 2025
Sale(S)
Direct
29.3K shares at avg. $20.22$592K
DNLI
Denali Therapeutics Inc.
Jan 3, 2025
Award(A)
Direct
54.2K shares-
DNLI
Denali Therapeutics Inc.
Oct 18, 2024
Sale(S)
Direct
40K shares at avg. $27.69$1.1M
DNLI
Denali Therapeutics Inc.
Oct 18, 2024
Exercise(M)
Direct
40K shares at avg. $0.68$27K

		Type	Shares	Price		Ownership
Aug 12, 2026	DNLI Denali Therapeutics Inc.	Gift(G)	32,220	-	$0	Indirect
Jan 6, 2026	DNLI Denali Therapeutics Inc.	Sale(S)	35,198	$16.50	$580,767	Direct
Jan 3, 2026	DNLI Denali Therapeutics Inc.	Award(A)	78,960	-	$0	Direct
Sep 3, 2025	DNLI Denali Therapeutics Inc.	Gift(G)	50,000	-	-	Indirect
Jul 9, 2025	DNLI Denali Therapeutics Inc.	Sale(S)	495,282	$15.00	$7,429,230	Direct
Jul 9, 2025	DNLI Denali Therapeutics Inc.	Exercise(M)	455,282	$0.68	$309,592	Direct
Jul 9, 2025	DNLI Denali Therapeutics Inc.	Exercise(M)	40,000	$5.28	$211,200	Direct
Jan 7, 2025	DNLI Denali Therapeutics Inc.	Sale(S)	7,650	$20.81	$159,197	Direct
Jan 6, 2025	DNLI Denali Therapeutics Inc.	Sale(S)	29,266	$20.22	$591,759	Direct
Jan 3, 2025	DNLI Denali Therapeutics Inc.	Award(A)	54,180	-	$0	Direct
Oct 18, 2024	DNLI Denali Therapeutics Inc.	Sale(S)	40,000	$27.69	$1,107,600	Direct
Oct 18, 2024	DNLI Denali Therapeutics Inc.	Exercise(M)	40,000	$0.68	$27,200	Direct

1-12 of 12 transactions

About Watts Ryan J.

Watts Ryan J. (SEC CIK 0001724310) files insider reports with the SEC as President and CEO of Denali Therapeutics Inc. (DNLI).

Signal8 holds 8 ownership filings by Watts Ryan J., all Form 4s, filed between Oct 22, 2024 and Aug 14, 2026. Those filings report 12 transactions, from Oct 18, 2024 to Aug 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Watts Ryan J.'s filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Watts Ryan J.

Aug 12, 2026: Gift of DNLI shares (Form 4, code G).
Jan 6, 2026: Open-market sale of DNLI shares (Form 4, code S).
Jan 3, 2026: Grant or award of DNLI shares (Form 4, code A).
Sep 3, 2025: Gift of DNLI shares (Form 4, code G).
Jul 9, 2025: Open-market sale of DNLI shares (Form 4, code S).

Other insiders filing for Denali Therapeutics Inc. (DNLI)

Chin Peter Scott, Chief Medical Officer
Thornberry Nancy, Director
Schuth Alexander O., COFO and Secretary
FLATLEY JAY T, Director
Klein Peter S, Director
Krognes Steve E., Director

How to read Form 4 transaction codes